文献速递先天性心脏病外科

先天性心脏病项目中小肠黏膜下层细胞外基质补片使用超过400例

More Than 400 Uses of an Intestinal Submucosal Extracellular Matrix Patch in a Congenital Heart Program.
PubMed 文献 · Ann Thorac Surg · 2021-08-08

该研究为单中心回顾性队列研究,评估2012至2019年间在先天性心脏病手术中使用小肠黏膜下层细胞外基质(SIS-ECM)补片的使用、有效性和安全性。共309例患者使用408块补片,中位随访3.9年,补片相关外科再干预率2.5%,经皮再干预率6.6%,无补片相关死亡或钙化报告。SIS-ECM是可行的补片选择,失败和钙化风险低。

要点

  • SIS-ECM补片可用于多种心脏和血管重建手术,失败和钙化风险低。
  • 最常见用途为肺动脉修复(44.4%),其次为其他动脉成形术(77%)。
  • 补片相关外科再干预率2.5%,经皮再干预率6.6%,无补片相关死亡。

核心结论

  • SIS-ECM是可行的补片选择,可用于多种心脏和血管重建手术,失败和钙化风险低。
  • 通过一致的技术和理解补片的适当应用,可能最大化长期积极结果。

研究设计与样本

  • 单中心、回顾性、队列研究,纳入2012年至2019年间使用SIS-ECM补片的手术。
  • 共309例患者(188例男性,121例女性;中位年龄8.5个月),使用408块SIS-ECM补片。
  • 补片数据按用途和类型(四层和两层)分类,所有再干预和并发症由独立外科医生、先天性心脏外科医生和儿科心脏病专家审查。

主要发现

  • 补片用途包括314例动脉成形术(77%)、22例静脉成形术(5.4%)、63例心内修复(15.4%)和9例瓣膜修复(2.2%)。
  • 最常见用途为肺动脉修复(n=181;44.4%)。
  • 中位随访时间3.9年(范围3天至7.4年)。

临床怎么用

  • SIS-ECM补片可作为先天性心脏病手术中多种心脏和血管重建的补片选择。
  • 使用中应保持技术一致并理解补片的适当应用,以优化长期结果。

局限性

  • 单中心回顾性研究设计。
  • 随访时间中位3.9年,长期结果仍需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Repair of complex congenital heart disease frequently requires use of a patch as an anatomic substitute. The study's aim is to evaluate the use, effectiveness, and safety of using small intestine submucosal extracellular matrix (SIS-ECM) patches in a congenital cardiac surgery program. METHODS: This is a single-center, retrospective, cohort study of surgeries using SIS-ECM between 2012 and 2019. The SIS-ECM data were categorized by use and type (four-ply and two-ply). All reinterventions and complications were reviewed by an independent surgeon, a practicing congenital heart surgeon, and a pediatric cardiologist. RESULTS: In all, 408 SIS-ECM patches were used in 309 patients (188 male, 121 female; median age 8.5 months). Use of the patches consisted of 314 arterioplasties (77%), 22 venoplasties (5.4%), 63 intracardiac repairs (15.4%), and 9 valve repairs (2.2%). The most common use was for pulmonary artery repair (n = 181; 44.4%). Median follow-up time was 3.9 years (range, 3 days to 7.4 years). Ten patches (2.5%) required surgical reintervention (2 in the first 30 days and 5 in the first year) and 27 (6.6%) required percutaneous reinterventions (2 in the first 30 days and 22 in the first year). Between four-ply (n = 376) and two-ply (n = 32) SIS-ECM, the rate of surgical (2.1% [n = 8] vs 6.3% [n = 2], P = .18) or percutaneous reinterventions (6.4% [n = 24] vs 9.4% [n = 3], P = .46) was not different. There were no deaths related to the SIS-ECM patch or reports of calcification. CONCLUSIONS: The SIS-ECM is a viable patch option that can be used in various cardiac and vascular reconstructive surgeries with low risk of failure and calcification. Long-term, positive outcomes may be maximized by using consistent techniques and understanding the appropriate applications of the patch.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Haney LC, Ahmed HF, Dani A, et al. More Than 400 Uses of an Intestinal Submucosal Extracellular Matrix Patch in a Congenital Heart Program. Ann Thorac Surg. 2021. PMID: 34375649. doi:10.1016/j.athoracsur.2021.06.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。